All In Biotech

Drug Trial Radar · NCT00598832

Clinical Study to Test the Efficacy and Safety of Adapalene, 0.1%

A Multi-Center, Randomized, Double-Blind, Parallel Group Study to Demonstrate the Efficacy and Safety of Adapalene Lotion, 0.1% Compared With Vehicle Lotion in Subjects With Acne Vulgaris

Last checked: Nov 19, 2026Latest source record: Feb 18, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,075 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,075

Actual

Start

Nov 2007

Primary completion

Oct 2008

Study completion Nov 2008

Sponsor

Lead sponsor
Galderma R&DIndustry
Sponsor type
Industry
First posted
Jan 23, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether Adapalene, 0.1% is safe and effective in the treatment of Acne Vulgaris.

Conditions

  • Acne Vulgaris

Interventions

  • Adapalene lotion 0.1%Drug

    Adapalene, 0.1% will be applied topically to the face, once a day, for 12 weeks

  • Adapalene Lotion VehicleDrug

    Adapalene Lotion Vehicle will be applied topically to the face, once a day, for 12 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Co-Primary Endpoint: Success Rate on Investigator's Global Assessment (IGA) From Baseline to Week 12Time frame: From Baseline to Week 12
  2. Co-Primary Endpoint: Absolute Change in Total Lesion Count From Baseline to Week 12Time frame: Baseline to Week 12
  3. Co-Primary Endpoint: Absolute Change in Inflammatory Lesion Count From Baseline to Week 12Time frame: Baseline to Week 12
  4. Co-Primary Endpoint: Absolute Change in NonInflammatory Lesion Counts From Baseline to Week 12Time frame: Baseline to Week 12

Locations

34 sites in 2 countries. Site status is shown where the registry gives one.

  • Burke Pharmaceutical Research

    Hot Springs, Arkansas

  • Scott Dinehart

    Little Rock, Arkansas

  • Dermatology and Laser Center

    Marina del Rey, California

  • Therapeutics Clinical Research

    San Diego, California

  • Solano Clinical Research

    Vallejo, California

  • Colorado Medical Research Center

    Denver, Colorado

  • Longmont Clinic

    Longmont, Colorado

  • Advanced Dermatology

    Clermont, Florida

  • International Dermatology Research, Inc.

    Miami, Florida

  • Anne M. Loebl

    Augusta, Georgia

  • Scott Glazer

    Buffalo Grove, Illinois

  • Sound Bend Clinic

    South Bend, Indiana

  • Hamzavi Dermatology

    Port Huron, Michigan

  • Central Dermatology, PC

    St Louis, Missouri

  • Darmouth-Hitchcock Medical Center Section of Dermatology

    Lebanon, New Hampshire

  • Academic Dermatology

    Albuquerque, New Mexico

  • Elizabeth Arthur

    Rochester, New York

  • Derm Research Center of New York

    Stony Brook, New York

  • Unifour Medical Research Associates

    Hickory, North Carolina

  • Haber Dermatology & Cosmetic Research

    South Euclid, Ohio

  • OU Health Sciences Center-Dept. of Dermatology

    Oklahoma City, Oklahoma

  • Oregon Medical Center, PC

    Portland, Oregon

  • Rivergate Dermatology

    Goodlettsville, Tennessee

  • DermResearch, Inc.

    Austin, Texas

  • Center for Clinical Studies

    Houston, Texas

  • Progressive Clinical Research

    San Antonio, Texas

  • Virginia Clinical Research, Inc.

    Norfolk, Virginia

  • The Dermatology Centre

    Calgary, Alberta, Canada

  • Stratica Medical

    Edmonton, Alberta, Canada

  • Guildford Dermatology Specialists

    Surrey, British Columbia, Canada

  • Dermadvance Research

    Winnipeg, Manitoba, Canada

  • Nexus Clinical Research

    St. John's, Newfoundland and Labrador, Canada

  • Lynderm Research, Inc.

    Markham, Ontario, Canada

  • K. Papp Clinical Research, Inc.

    Waterloo, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.